or Try an Advanced Search...

    Halozyme Stocks List

    Symbol Grade Name % Change
    HALO B Halozyme Therapeutics, Inc. 2.48
    NXTC F NextCure, Inc. -0.75
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Halozyme stocks.

    Symbol Grade Name Weight
    FBT A First Trust Amex Biotech Index Fund 3.2
    CSMD D Congress SMid Growth ETF 2.39
    PBE C PowerShares Dynamic Biotech & Genome 2.25
    GSC D Goldman Sachs Small Cap Core Equity ETF 1.55
    BBP A BioShares Biotechnology Products Fund 1.47
    View all Halozyme ETFs...
    Compare ETFs
    Compare CSMD to GSC Compare FBT to GSC Compare GSC to BBP

        Halozyme Stocks Recent News

        Date Stock Title
        Nov 4 HALO Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
        Nov 3 HALO Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
        Nov 1 HALO Top High Growth Tech Stocks To Watch In November 2024
        Nov 1 HALO Halozyme Announces Record Earnings, Guidance
        Nov 1 HALO HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
        Nov 1 HALO Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
        Nov 1 HALO Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
        Oct 31 HALO Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
        Oct 31 HALO Halozyme Therapeutics, Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 HALO Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say
        Oct 31 HALO Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
        Oct 31 HALO Halozyme Therapeutics: Q3 Earnings Snapshot
        Oct 31 HALO Halozyme Therapeutics Non-GAAP EPS of $1.27 beats by $0.27, revenue of $290.1M beats by $37.93M
        Oct 31 HALO HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
        Oct 30 HALO Halozyme Therapeutics Q3 2024 Earnings Preview
        Oct 30 HALO A Look Ahead: Halozyme Therapeutics's Earnings Forecast
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine
        Halozyme

        Halozyme Therapeutics is a U.S. biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.
        The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

        More about Halozyme
        Browse All Tags